Ceribell, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
CBLL$26.59+2.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
| Name | Action | Date | Trading Arrangement | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Josef Parvizi, M.D., Ph.D.Director, Chief Medical Advisor, and Co-Founder | Adopt | August 12, 2026 | X | 250,000 | July 26, 2027 |
| William W. BurkeDirector | Adopt | August 12, 2026 | X | 19,960 | July 7, 2027 |
| Xingjuan (Jane) ChaoPresident, Chief Executive Officer, Director, and Co-Founder | Adopt | August 12, 2026 | X | 472,500 | September 30, 2027 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.